NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals this week announced that the European Patent Office has overturned the claims of one of its patents covering compositions, methods, and uses of siRNAs between 15 and 49 nucleotides long.

The patent in question, EP 1214945, is part of Alnylam's so-called Kreutzer-Limmer patent estate, which the company acquired when it bought German RNAi shop Ribopharma in 2003.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.